Keylika

2 employees

Keylika developed a platform synthesis technology that is used to generate multitude of organometallic drugs.

Basic info

biotechnology research

drug development

transdermal

IDA

organometallic drugs

first principles design

Bioinorganic drugs

formulation

drug delivery

Clinical Trials

Iron deficiency anemia

platform synthesis technology

Medical

transdermal patch

2022

Keylika raised undisclosed on August 22, 2022

Investors: Y Combinator